A Double-Blind Randomized-Phase II Trial Comparing Immunization with Antiidiotype Goat Antibody Vaccine SCV 106 Versus Unspecific Goat Antibodies in Patients with Metastatic Colorectal Cancer

Phase Ii ◽

Phase Ii Trial ◽

Double Blind ◽

Randomized Phase Ii

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Multicenter randomized phase II trial (BEVATOMOX) assessing the raltitrexed, oxaliplatin and bevacizumab combination versus FOLFOX6 bevacizumab as 2nd line treatment in metastatic colorectal cancer (mCRC)

Annals of Oncology ◽

10.1093/annonc/mdx393.055 ◽

2017 ◽

Vol 28 ◽

pp. v179

Author(s):

E. Samalin ◽

H. Senellart ◽

S. Thezenas ◽

S. Jacquot ◽

S. Ellis ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Randomized Phase Ii

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Cited By ~ 1

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Abstract 373: Circulating endothelial cell measurement allows early prediction of outcome in patients with metastatic colorectal cancer treated with first-line bevacizumab and chemotherapy. Findings from the FNCLCC ACCORD 13/0503 randomized phase II trial

10.1158/1538-7445.am10-373 ◽

2010 ◽

Author(s):

Valerie Boige ◽

Jean Mendiboure ◽

Antoine Adenis ◽

Evelyne Boucher ◽

Jean-Yves Pierga ◽

...

Keyword(s):

Colorectal Cancer ◽

Endothelial Cell ◽

Phase Ii ◽

Phase Ii Trial ◽

Early Prediction ◽

Prediction Of Outcome ◽

First Line ◽

Randomized Phase Ii ◽

Cell Measurement

Intermittent or continuous panitumumab (PAN) plus FOLFIRI for first-line treatment of patients (pts) with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC): A randomized phase II trial (IMPROVE)

Annals of Oncology ◽

10.1093/annonc/mdy281.154 ◽

2018 ◽

Vol 29 ◽

pp. viii202

Author(s):

A. De Stefano ◽

G. Nasti ◽

A. Febbraro ◽

G. Rosati ◽

F. Giuliani ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Randomized Phase Ii ◽

HGCSG1301: A multicenter, double-blind, randomized control phase II trial comparing Hange-shashin-to versus placebo to prevent diarrhea in patients with metastatic colorectal cancer under IRIS/Bev second-line treatment

Annals of Oncology ◽

10.1093/annonc/mdy431.029 ◽

2018 ◽

Vol 29 ◽

pp. ix37

Author(s):

M. Dazai ◽

S. Yuki ◽

K. Sawada ◽

T. Muranaka ◽

Y. Kawamoto ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

Second Line ◽

Double Blind ◽

Control Phase ◽

Randomized Control

Neuroprotective effects of goshajinkigan (TJ-107) in colorectal cancer patients receiving oxaliplatin-based chemotherapy: A double-blind, placebo-controlled, randomized phase II trial from the GONE Study Group.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.e14007 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. e14007-e14007 ◽

Cited By ~ 1

Author(s):

T. Matsui ◽

T. Kono ◽

T. Hata ◽

Y. Munemoto ◽

M. Fukunaga ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Neuroprotective Effects ◽

Double Blind ◽

Double Blind Placebo ◽

Randomized Phase Ii ◽

Colorectal Cancer Patients

PRODIGE 20: Bevacizumab + chemotherapy (BEV-CT) versus chemotherapy alone (CT) in elderly patients (pts) with untreated metastatic colorectal cancer (mCRC)—A randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.3541 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. 3541-3541 ◽

Cited By ~ 5

Author(s):

Thomas Aparicio ◽

Olivier Bouche ◽

Eric Francois ◽

Emilie Maillard ◽

Sylvie Kirscher ◽

...

Keyword(s):

Colorectal Cancer ◽

Elderly Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii